Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Fraser Palamara explains why LTR Pharma (ASX:LTP) could shake up erectile dysfunction remedies.

The company shared news today its SPONTAN nasal spray treatment impressed in a bio-equivalence study – showing strong promise to disrupt the traditional PDE5 oral remedy market. The study demonstrated positive results in drug dosage and rate efficiency.

Tune in to get the latest.